Record Electron Deal Lifts Backlog, But Neutron and Dilution Overhangs Keep RKLB a WAIT

What happened

Rocket Lab shares rose 5% after announcing its largest-ever Electron launch contract, pushing backlog past 100 missions and attracting a new bullish Wall Street initiation. The contract reinforces demand for Electron but does not address the primary concerns in our WAIT thesis: Neutron first launch remains targeted for Q4 2026 with a narrowing window, and the pending Iridium acquisition has already driven significant share dilution. The stock is trading around $74, above our $60 attractive entry, and current valuation already prices in successful Neutron milestones and margin improvement. While the record deal confirms strong customer demand, it does not change the need for hard evidence of Neutron progress or a better risk-reward entry point.

Implication

The record Electron contract strengthens Rocket Lab's launch backlog but does not remove the key overhangs that justify a WAIT rating at the current price. Investors should watch for two concrete events: Neutron pad delivery or integrated static-fire disclosure by year-end, and Q4 adjusted EBITDA loss narrowing below $15 million. The stock is priced for success, leaving little room for error; any slip in Neutron or further dilution would likely pressure the shares toward the $60 area. If the stock pulls back toward $60, risk-reward improves materially for patient investors. Conversely, a break above $88 would suggest the market is assigning additional credit not yet backed by milestones, and trimming into strength would be prudent.

Thesis delta

The thesis remains unchanged: Rocket Lab's integrated space systems model is validated by growing backlog, but the current valuation already reflects strong execution. The record Electron deal is a positive demand signal but does not address Neutron timing risk or the dilutive Iridium financing. No change to WAIT rating; the attractive entry point remains $60, and a breakout above $88 would warrant trimming.